Equities Analysts Offer Predictions for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – HC Wainwright lowered their Q2 2026 EPS estimates for shares of Vera Therapeutics in a research note issued on Tuesday, May 12th. HC Wainwright analyst A. He now expects that the company will earn ($1.70) per share for the quarter, down from their prior estimate of ($1.31). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($5.74) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2026 earnings at ($1.57) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($2.08) EPS, FY2028 earnings at $2.20 EPS, FY2029 earnings at $9.11 EPS and FY2030 earnings at $10.83 EPS.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the prior year, the business posted ($0.81) EPS.

Several other analysts have also recently weighed in on VERA. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.60.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $39.15 on Thursday. The firm has a 50 day simple moving average of $39.63 and a 200-day simple moving average of $40.56. Vera Therapeutics has a 1-year low of $18.76 and a 1-year high of $56.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of -7.07 and a beta of 0.96.

Institutional Trading of Vera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares in the last quarter. Optimize Financial Inc raised its position in Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after acquiring an additional 256 shares during the last quarter. Virtus Investment Advisers LLC raised its position in Vera Therapeutics by 5.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after acquiring an additional 290 shares during the last quarter. Intech Investment Management LLC raised its position in Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after acquiring an additional 424 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after buying an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Activity

In related news, CFO Sean Grant sold 4,949 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the sale, the chief financial officer directly owned 114,181 shares in the company, valued at $4,793,318.38. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO David Lee Johnson sold 2,579 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $108,266.42. Following the sale, the chief operating officer owned 45,727 shares in the company, valued at $1,919,619.46. This represents a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 74,941 shares of company stock worth $3,096,592 over the last three months. Company insiders own 15.90% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.